CABINET:
LIVE

Serial Number

88241679

Owner

Patel & Gong, Inc.

First Use Date

Jul 28, 2020

Filing Date

Dec 26, 2018

Add to watchlist:

No watchlists yet
View on USPTO

CABINET: Trademark

Serial Number: 88241679 • Registration: 7101112

CABINET: is a trademark filed by Patel & Gong, Inc. on December 26, 2018. The trademark is classified under Class 5 (Pharmaceuticals), Class 9 (Computers & Electronics), Class 42 (Computer & Scientific), Class 35 (Advertising & Business). The application is currently registered and active.

Owner Contact Info

Patel & Gong, Inc. (7 trademarks)

Washington, DC 20001

Entity Type: 03

Trademark Details

Filing Date

December 26, 2018

Registration Date

July 4, 2023

First Use Anywhere

July 28, 2020

First Use in Commerce

July 28, 2020

Published for Opposition

March 10, 2020

Goods & Services

Providing online non-downloadable mobile applications for use in obtaining prescription and over the counter medications and referrals to healthcare providers

Downloadable software in the nature of a mobile application for use in connection with the collection, analysis, and sharing of personal medical data; Downloadable mobile applications for use in obtaining prescription and over the counter medications and referrals to healthcare providers; Downloadable mobile applications featuring pricing information for prescription drugs and over the counter medications, for purchasing of prescription drugs and over the counter medications, and for providing information regarding health, prescription drugs and over the counter medications

Retail pharmacy services; Retail store services for pharmaceutical and medical supplies

Pharmaceutical anti-allergic preparations and substances; Pharmaceutical preparations acting on the central nervous system; Pharmaceutical preparations and substances for the treatment of gastro-intestinal diseases; Pharmaceutical preparations and substances for the treatment of infectious diseases, blood disorders, pain, inflammation, sepsis, alopecia, obesity and cognitive disorders; Pharmaceutical preparations and substances for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; Pharmaceutical preparations for inhalation for the treatment of pulmonary hypertension; Pharmaceutical preparations for peripheral nervous system; Pharmaceutical preparations for skin care; Pharmaceutical preparations for skin wounds; Pharmaceutical preparations for the prevention and treatment of ocular disorders or diseases, bacteria-based diseases or disorders, autoimmune diseases or disorders, kidney diseases or disorders, and diabetes; Pharmaceutical preparations for the treatment of eye diseases and conditions; Pharmaceutical preparations for the treatment of heart rhythm disorders; Pharmaceutical preparations for the treatment of hormonal disorders and the prevention of osteoporosis; Pharmaceutical preparations for the treatment of immune system related diseases and disorders; Pharmaceutical preparations for the treatment of infectious diseases; Pharmaceutical preparations for the treatment of kidney diseases; Pharmaceutical preparations for the treatment of musculo-skeletal disorders; Pharmaceutical preparations for treating allergic rhinitis and asthma; Pharmaceutical preparations for treating allergies; Pharmaceutical preparations for treating and preventing tendon and muscle injuries and disorders, sports related injuries, and for knee cartilage regeneration; Pharmaceutical preparations for treating diabetes; Pharmaceutical preparations for treating skin disorders; Pharmaceutical preparations for treating sunburn; Pharmaceutical preparations for use in dermatology; Pharmaceutical preparations for use in urology; Pharmaceutical preparations, namely, a drug delivery system comprising polymer-based oral tablets for the continuous release of a wide variety of therapeutic agents; Pharmaceutical preparations, namely, a topical preparation for the treatment of ocular disorders prescribed by ophthalmologists, eye surgeons, and optometrists; Pharmaceutical preparations, namely, an analgesic for human consumption taken orally; Pharmaceutical preparations, namely, anticoagulants; Pharmaceutical preparations, namely, antidepressants; Pharmaceutical preparations, namely, antivirals; Pharmaceutical preparations, namely, appetite suppressants; Pharmaceutical preparations, namely, injectable contraceptives; Pharmaceutical products and preparations against dry skin caused by pregnancy; Pharmaceutical products and preparations for hydrating the skin during pregnancy; Pharmaceutical products and preparations for preventing skin blemishes during pregnancy; Pharmaceutical products and preparations to prevent swelling in the legs; Analgesic and muscle relaxant pharmaceutical preparations

Filing History

CANCELLATION INSTITUTED NO. 999999
Apr 5, 2025 PETC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
Jul 4, 2023 NRCC
REGISTERED-PRINCIPAL REGISTER
Jul 4, 2023 R.PR
NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
May 27, 2023 SUNA
ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
May 26, 2023 CNPR
STATEMENT OF USE PROCESSING COMPLETE
May 11, 2023 SUPC
USE AMENDMENT FILED
May 5, 2023 IUAF
TEAS STATEMENT OF USE RECEIVED
May 5, 2023 EISU
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Nov 10, 2022 EXRA
SOU EXTENSION 5 GRANTED
Nov 9, 2022 EX5G
SOU EXTENSION 5 FILED
Nov 7, 2022 EXT5
SOU TEAS EXTENSION RECEIVED
Nov 7, 2022 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Sep 1, 2022 EXRA
SOU EXTENSION 4 GRANTED
Aug 31, 2022 EX4G
CASE ASSIGNED TO INTENT TO USE PARALEGAL
Aug 30, 2022 AITU
NOTICE OF REVIVAL - E-MAILED
Aug 6, 2022 NREV
SOU EXTENSION RECEIVED WITH TEAS PETITION
Aug 5, 2022 TPEX
PETITION TO REVIVE-GRANTED
Aug 5, 2022 PETG
TEAS PETITION TO REVIVE RECEIVED
Aug 5, 2022 PROA
ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
Jun 6, 2022 MAB6
ABANDONMENT - NO USE STATEMENT FILED
Jun 6, 2022 ABN6
SOU EXTENSION 4 FILED
May 5, 2022 EXT4
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Nov 9, 2021 EXRA
SOU EXTENSION 3 GRANTED
Nov 5, 2021 EX3G
SOU EXTENSION 3 FILED
Nov 5, 2021 EXT3
SOU TEAS EXTENSION RECEIVED
Nov 5, 2021 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
May 7, 2021 EXRA
SOU EXTENSION 2 GRANTED
May 5, 2021 EX2G
SOU EXTENSION 2 FILED
May 5, 2021 EXT2
SOU TEAS EXTENSION RECEIVED
May 5, 2021 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Nov 7, 2020 EXRA
SOU EXTENSION 1 GRANTED
Nov 5, 2020 EX1G
SOU EXTENSION 1 FILED
Nov 5, 2020 EXT1
SOU TEAS EXTENSION RECEIVED
Nov 5, 2020 EEXT
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
May 5, 2020 NOAM
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Mar 10, 2020 NPUB
PUBLISHED FOR OPPOSITION
Mar 10, 2020 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Feb 19, 2020 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Feb 4, 2020 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Jan 23, 2020 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jan 23, 2020 CRFA
TEAS REQUEST FOR RECONSIDERATION RECEIVED
Jan 23, 2020 ERFR
NOTIFICATION OF FINAL REFUSAL EMAILED
Nov 5, 2019 GNFN
FINAL REFUSAL E-MAILED
Nov 5, 2019 GNFR
FINAL REFUSAL WRITTEN
Nov 5, 2019 CNFR
TEAS/EMAIL CORRESPONDENCE ENTERED
Oct 4, 2019 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Oct 1, 2019 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Oct 1, 2019 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Apr 1, 2019 GNRN
NON-FINAL ACTION E-MAILED
Apr 1, 2019 GNRT
NON-FINAL ACTION WRITTEN
Apr 1, 2019 CNRT
REMOVED FROM TEAS PLUS
Apr 1, 2019 RFTP
ASSIGNED TO EXAMINER
Mar 19, 2019 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Jan 17, 2019 NWOS
NEW APPLICATION ENTERED
Dec 29, 2018 NWAP